FRC-222 is a CHD1 tandem chromodomain inhibitor with a Kd of 0.15 µM and an IC50 of 0.18 µM. FRC-222 binds to the H3K4me3 binding site of CHD1 tandem chromodomain via aromatic cage interactions and extended ligand contacts. FRC-222 can be used for the research of prostate cancer[1].
Molecular Weight:
579.77
Formula:
C36H45N5O2
Target:
DNA/RNA Synthesis
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
